Item 1.01. Entry into a Material Definitive Agreement
Business Combination Agreement
SCS is a blank check company incorporated as a
Following the closing of the transactions contemplated by the Business
Combination Agreement (the "Closing"), the combined company will be organized in
an umbrella partnership-C corporation (a so called "Up-C") structure, and SCS's
direct assets will consist of common units of ProKidney ("ProKidney Common
Units") and equity interests of a private limited company organized under the
laws of
The Business Combination
The Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, the following transactions will occur at the Closing (together with the other transactions contemplated by the Business Combination Agreement, the "Business Combination"):
(i) ProKidney will issue to SCS a number of ProKidney Common Units equal to the number of fully diluted outstanding SCS ordinary shares as of immediately prior to the Closing (but after giving effect to all redemptions of SCS Class A ordinary shares, par value$0.0001 per share ("SCS Class A Common Stock") and thePIPE Investment (as defined below)), in exchange for (a) SCS Class B ordinary shares, par value$0.0001 per share ("SCS Class B Common Stock" and, together with the SCS Class A Common Stock, the "SCS Common Stock"), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of SCS are entitled to vote generally, (b) an amount in cash equal to the aggregate proceeds obtained by SCS in thePIPE Investment and (c) an amount in cash equal to the aggregate proceeds available for release to SCS from SCS's trust account (the "Trust Account") (after giving effect to all redemptions of shares of SCS Class A Common Stock and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (ii) Legacy GP will resign as the general partner of ProKidney and New GP will be admitted as the general partner of ProKidney; (iii) existing ProKidney unitholders will continue to hold the ProKidney Common Units held as of immediately prior to the Closing and ProKidney will also distribute to such unitholders the shares of SCS Class B Common Stock received pursuant to clause (i)(A) above; and (iv) existing ProKidney unitholders will receive an aggregate of 17,500,000 restricted common units of ProKidney and 17,500,000 restricted stock rights in respect of shares of SCS Class B Common Stock (collectively, the "Earnout Rights"), which Earnout Rights will vest in three equal tranches 2
--------------------------------------------------------------------------------
(and settle into ProKidney Common Units and shares of SCS ClassB Common Stock, respectively) upon the trading price of a share of SCS Class A Common Stock reaching$15.00 /share,$20.00 /share and$25.00 /share, respectively, on the terms set forth in the Business Combination Agreement (collectively, the "Earnout").
Following the Closing, pursuant to the Exchange Agreement described below, each ProKidney Common Unit, together with one share of SCS Class B Common Stock, will generally be exchangeable for one share of SCS Class A Common Stock, subject to certain procedures and restrictions.
The Board of Directors of SCS (the "Board") has unanimously (i) approved and declared advisable the Business Combination Agreement, the Business Combination and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Business Combination Agreement and related matters by the shareholders of SCS. Concurrently with the execution of the Business Combination Agreement, the requisite ProKidney unitholders consented to and approved the Business Combination Agreement and the transactions contemplated thereby.
Conditions to the Closing
The Business Combination is subject to the satisfaction or waiver of certain customary closing conditions, including, among others, (i) approval of the Business Combination and related matters by the shareholders of SCS, (ii) the absence of any injunctions prohibiting the transactions, (iii) the accuracy (subject to agreed materiality thresholds) of the parties' representations and warranties contained in the Business Combination Agreement, and (iv) the parties' compliance in all material respects with their respective covenants under the Business Combination Agreement.
In addition, ProKidney's obligation to consummate the Business Combination is
conditional on SCS having an amount of cash available at the Closing of at least
Covenants
The Business Combination Agreement contains customary covenants, including,
among others, providing for, with customary exceptions, (i) the parties to use
reasonable best efforts to conduct their respective businesses in the ordinary
course consistent with past practice through the Closing, (ii) the parties to
not initiate any negotiations or enter into any agreements for certain
alternative transactions, (iii) ProKidney to prepare and deliver to SCS certain
audited and unaudited consolidated financial statements of ProKidney, (iv) SCS
to prepare and file a proxy statement and take certain other actions to obtain
the requisite approval of SCS shareholders of certain proposals regarding the
Business Combination, (v) cooperation with respect to the
Pursuant to the Business Combination Agreement, subject to the terms of SCS's
governing documents, SCS must take all necessary or appropriate action such
that, immediately following the Closing, the Board will consist of three classes
and a minimum of seven and a maximum of nine directors, at least a majority of
whom shall be "independent" directors for purposes of the rules of
3
--------------------------------------------------------------------------------
Representations and Warranties
The Business Combination Agreement contains customary representations and warranties by SCS and ProKidney. These representations and warranties generally will not survive the Closing.
Termination
The Business Combination Agreement may be terminated at any time prior to the Closing (i) by written consent of SCS and ProKidney, (ii) by ProKidney, if certain approvals of the shareholders of SCS, to the extent required under the . . .
Item 3.02 Unregistered Sales of
The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K
with respect to the
Additional Information and Where to Find It
In connection with the proposed transaction, SCS intends to file a preliminary
proxy statement and a definitive proxy statement with the
7
--------------------------------------------------------------------------------
The documents filed by SCS with the
Participants in Solicitation
SCS and ProKidney and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from SCS's shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction between ProKidney and SCS will be contained in the proxy statement when available. You may obtain free copies of these documents as described in the preceding paragraph.
No Offer or Solicitation
This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.
Cautionary Statement Regarding Forward-Looking Statements
This communication may contain certain forward-looking statements within the
meaning of the federal securities laws with respect to the proposed transaction
between ProKidney and SCS. These forward-looking statements generally are
identified by the words "believe," "project," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely result," and
similar expressions. Forward-looking statements are predictions, projections and
other statements about future events that are based on current expectations and
assumptions and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future events to differ materially from the
forward-looking statements in this communication, including but not limited to:
(i) the risk that the proposed transaction may not be completed in a timely
manner or at all, which may adversely affect the price of SCS's securities,
(ii) the risk that the proposed transaction may not be completed by SCS's
business combination deadline and the potential failure to obtain an extension
of the business combination deadline if sought by SCS, (iii) the failure to
satisfy the conditions to the consummation of the proposed transaction,
including the adoption of the Business Combination Agreement by the shareholders
of SCS and the satisfaction of the minimum cash condition, (iv) the lack of a
third party valuation in determining whether or not to pursue the proposed
transaction, (v) the inability to complete the
8
--------------------------------------------------------------------------------
Readers are cautioned not to put undue reliance on forward-looking statements, and ProKidney and SCS assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither ProKidney nor SCS gives any assurance that either ProKidney or SCS, or the combined company, will achieve its expectations.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 2.1* Business Combination Agreement, dated as ofJanuary 18, 2022 10.1 Form of Subscription Agreement forInstitutional Investors 10.2 Form of Subscription Agreement forIndividual Investors 10.3 Sponsor Support Agreement, dated as ofJanuary 18, 2022 10.4 ProKidney Unitholder Support Agreement, dated as ofJanuary 18, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Certain of the exhibits and schedules to this exhibit have been omitted in
accordance with Regulation S-K Item 601(b)(2). The registrant agrees to furnish
supplementally a copy of all omitted exhibits and schedules to the
request. 9
--------------------------------------------------------------------------------
© Edgar Online, source